Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Divestments (2017 - 2022)

Integra Lifesciences Holdings' Divestments history spans 5 years, with the latest figure at $24.0 million for Q3 2022.

  • For Q3 2022, Divestments rose 1989.59% year-over-year to $24.0 million; the TTM value through Dec 2023 reached $24.0 million, changed 0.0%, while the annual FY2022 figure was $24.0 million, 87.42% down from the prior year.
  • Divestments for Q3 2022 was $24.0 million at Integra Lifesciences Holdings, up from -$1.3 million in the prior quarter.
  • Across five years, Divestments topped out at $191.7 million in Q1 2021 and bottomed at -$1.3 million in Q3 2021.
  • The 3-year median for Divestments is $14.8 million (2018), against an average of $55.0 million.
  • The largest annual shift saw Divestments skyrocketed 102.95% in 2018 before it skyrocketed 1989.59% in 2022.
  • A 3-year view of Divestments shows it stood at $5.7 million in 2018, then tumbled by 122.17% to -$1.3 million in 2021, then surged by 1989.59% to $24.0 million in 2022.
  • Per Business Quant, the three most recent readings for IART's Divestments are $24.0 million (Q3 2022), -$1.3 million (Q3 2021), and $191.7 million (Q1 2021).